logo.jpg
ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline
13 juin 2022 01h00 HE | ImCheck Therapeutics SAS
Significant round will enable the Company to advance ICT01, its lead anti-butyrophilin 3A antibody, to completion of randomized Phase II trialsSeries C adds global investors Earlybird, Andera...
logo.jpg
ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
12 nov. 2021 14h20 HE | ImCheck Therapeutics SAS
Oral presentation includes positive safety data across a wide range of ICT01 doses and efficacy data from patients receiving ICT01 plus pembrolizumab confirming durable clinical responses at low ICT01...
logo.jpg
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
26 avr. 2021 05h00 HE | ImCheck Therapeutics SAS
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 -- EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune...
logo.jpg
Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response
09 avr. 2021 00h01 HE | ImCheck Therapeutics SAS
ICT01 activates γ9δ2 T cells that rapidly migrate out of the circulation and secrete IFNγ and TNFα leading to an expanded immune system activationIncreased densities of activated and proliferating γδ,...
logo.jpg
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
15 sept. 2020 05h00 HE | ImCheck Therapeutics SAS
ImCheck Announces Investment by BB Pureos Bioventuresto Close Series B Fundraising with Total of €54 million ($64 million) Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced...
logo.jpg
First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
26 mars 2020 06h00 HE | ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors -- Marseille, France, March 26, 2020 –...